Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P61764

UPID:
STXB1_HUMAN

ALTERNATIVE NAMES:
MUNC18-1; N-Sec1; Protein unc-18 homolog 1; Protein unc-18 homolog A; p67

ALTERNATIVE UPACC:
P61764; B1AM97; Q28208; Q62759; Q64320; Q68CM6; Q96TG8

BACKGROUND:
Syntaxin-binding protein 1, also referred to as MUNC18-1 or N-Sec1, is integral to the regulation of synaptic vesicle docking and fusion. It binds syntaxin in a 1:1 ratio, interacting with syntaxins 1, 2, and 3, but not 4. Through its essential role in neurotransmitter release, it mediates the assembly of the SNARE complex at synaptic membranes, determining the specificity of intracellular fusion reactions.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Developmental and epileptic encephalopathy 4, characterized by frequent tonic seizures and profound intellectual disability, Syntaxin-binding protein 1 represents a promising target for therapeutic development. Exploring its function further could lead to novel treatments for epilepsy and enhance our understanding of synaptic transmission mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.